Open AccessManagement of macular edema due to central retinal vein occlusion – The role of aflibercept
Author(s) -
William Rhoades,
Drew Dickson,
Quan Dong Nguyen,
V. Diana
Publication year - 2017
Publication title -
taiwan journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.519
H-Index - 9
eISSN - 2211-5072
pISSN - 2211-5056
DOI - 10.4103/tjo.tjo_9_17
Subject(s) - aflibercept , medicine , central retinal vein occlusion , macular edema , ranibizumab , ophthalmology , bevacizumab , retinal vein , retinal , vascular endothelial growth factor , central retinal vein , surgery , vegf receptors , chemotherapy
Central retinal vein occlusion (CRVO) can cause vision loss. The pathogenesis of CRVO involves a thrombus formation leading to increased retinal capillary pressure, increased vascular permeability, and possibly retinal neovascularization. Vision loss due to CRVO is commonly caused by macular edema. Multiple treatment modalities have been used to treat macular edema. Currently, the most common therapy used is intravitreal inhibition of vascular endothelial growth factor (VEGF). The three most widely used agents are aflibercept, bevacizumab, and ranibizumab and they are effective at blocking VEGF. In addition, intraocular steroids can be used to treat macular edema. This review will briefly cover the treatment options and discuss in greater detail the efficacy and safety of aflibercept.